|
市場調査レポート
商品コード
1261462
微生物発酵技術の世界市場規模、シェア、産業動向分析レポートアプリケーション別、エンドユーザー別、地域別展望と予測、2022年~2028年Global Microbial Fermentation Technology Market Size, Share & Industry Trends Analysis Report By Application, By End User, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
微生物発酵技術の世界市場規模、シェア、産業動向分析レポートアプリケーション別、エンドユーザー別、地域別展望と予測、2022年~2028年 |
出版日: 2023年03月31日
発行: KBV Research
ページ情報: 英文 216 Pages
納期: 即納可能
|
微生物発酵技術市場規模は、2028年には424億米ドルに達し、予測期間中にCAGR5.4%の市場成長率で上昇すると予測されています。
製品や基質の評価、顕微鏡検査、毒性試験、またはバイオマスのモニタリングのような多くの技術は、菌株の形質や要件の包括的なイメージを提供し、特定の発酵プロセスの制御を可能にするのに役立ちます。酵母は単細胞の微生物で、エタノールと二酸化炭素を生成してパルプ発酵に参加する一方、ビタミン、アミノ酸、その他の代謝物を生成して細菌の増殖を助ける。
また、必要な芳香成分やタンパク質分解・脂肪分解活性も備えています。酵母を発酵させる工程には、ビール、ワイン、サイダー発酵などのアルコール発酵と、コーヒー、パン、チョコレート発酵などのノンアルコール酵母発酵があります。酵母は単細胞の真核微小菌で、自然界のいたるところに生息しています。真菌類と呼ばれる生物の一種で、キノコやカビも含まれます。
COVID-19の影響分析
世界の市場は、微生物ベースの医薬品の生産量を増加させるため、微生物株生産技術に注目し始めました。さらに、政府は、腸内環境を改善し免疫力を高める予防接種、医薬品、製品の研究において、中小および大手のバイオテクノロジー企業を支援しています。そのため、パンデミックは、この技術に関連する研究開発プロセスのスピードアップに貢献しました。しかし、産業の閉鎖やサプライチェーンの混乱により、それ以外の分野では技術の活用ができなくなっています。その結果、パンデミックは微生物発酵技術市場に中程度の影響を及ぼしました。
市場の成長要因
アルコール飲料の需要拡大
ホテル、レストラン、居酒屋、パブなどでは、アルコール飲料の需要が高まっています。毎年、ワイン、スピリッツ、ビールは世界中で約4,460億リットル消費されています。ビール、ラガー、サイダーは全アルコール消費量の約4,000億リットルを占め、ワインとスピリッツはそれぞれ2位、3位を占めています。また、多くの発展途上国で職人の手による蒸留酒の需要が高まっていることから、アルコール飲料の産業は増加すると予測されています。したがって、アルコール飲料の需要が高まるにつれて、微生物発酵技術の需要が促進され、市場の成長が確実なものになると思われます。
食品強化における技術の活用が進む
Pleurotus ostreatusを用いた固体発酵により、機械的に制御されたカノーラミールのタンパク質量は増加し、グルコシノレートとフィテートの量はそれぞれ最大98.8%と75.8%まで減少しました。また、大豆ミール(SBM)では、固体発酵によりアミノ酸とタンパク質の含有量が増加し、A. oryzaeよりもB. subtilisの方が大きな影響を与えました。これらの確立された実験結果は、微生物発酵技術の使用事例を拡大するものです。したがって、微生物発酵技術市場は、これらの要因によって、今後数年間で拡大すると考えられます。
市場抑制要因
発酵工程にまつわる問題
発酵食品は、自然変動が継続的に起こるため、時間の経過とともに汚染される可能性があります。しかし、変動がなくても汚染源による汚染は容易です。さらに、不純物が多いため、より多くの加工が必要になります。その結果、悪い細菌が増殖し、有益な微生物が滅びてしまうという、意図しない不快な事態が発生しました。固体発酵のような一般的な発酵プロセスには、低水分レベルにしか耐えられない微生物を使用したり、SSFを正確にモニターできないなどの欠点もあります。したがって、微生物発酵プロセスに関連するこのような困難は、今後数年間、市場の成長を妨げる可能性があります。
アプリケーションの展望
用途に基づき、微生物発酵技術市場は抗生物質、プロバイオティクスサプリメント、モノクローナル抗体、組み換えタンパク質、バイオシミラー、ワクチン、酵素、低分子、その他に分類されます。2021年の微生物発酵技術市場では、モノクローナル抗体分野がかなりの成長率を調達しています。さまざまな用途で最も有用な生物製剤の1つが、モノクローナル抗体です。これらの化合物の高い結合親和性、選択性、特異性により、しばしば有利になります。
エンドユーザーの展望
エンドユーザー別に見ると、微生物発酵技術市場は、バイオ製薬会社、契約研究機関(CRO)、CMO&CDMO、学術・研究機関に分けられます。2021年の微生物発酵技術市場では、受託製造機関(CRO)および受託開発・製造機関(CDMO)セグメントが最大の収益シェアを示しました。バイオプロセス産業における発明の大部分は、これらの製品の開発に必要な能力、熟練した人材、リソースを持たない中小企業によって生産されているため、CMOとCDMOはバイオ治療薬の生産者にとって好ましい選択肢に急速に進化しています。
地域別展望
地域別に見ると、微生物発酵技術市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。アジア太平洋地域は、2021年の微生物発酵技術市場で最大の収益シェアを獲得しました。これは、アジア諸国がバイオ医薬品産業におけるアウトソーシングの中心地であると認識されていることに起因します。世界の新しいバイオプロセス施設の推定50%は、国内の競合企業や国際的な強豪企業を含むアジアの企業によって建設されています。例えば、中国は国内需要に対応するため、複数のバイオプロセス施設の建設を計画しています。
List of Figures
The Global Microbial Fermentation Technology Market size is expected to reach $42.4 billion by 2028, rising at a market growth of 5.4% CAGR during the forecast period.
Microbial fermentation technology is novel, promising, and increasing quickly. This field uses microbes to produce substances with enormous applications in manufacturing biofuels, pharmaceuticals, environmentally friendly materials, fine chemicals, energy, and the food sector. For decades, this technology has been employed in producing highly prized goods. Still, to accomplish the shift to a bio-based society, it is urgently necessary to dramatically speed this technology's development.
Also, there is constant interest in and demand for developing novel microbial fermentation methods for several crucial reasons, including the potential to produce novel compounds and the sustainability element. One of the most crucial elements of contemporary biotechnology is fermentation engineering, which has been widely used in many fields.
Many techniques, like product and substrate evaluation, microscopy, toxicity tests, or biomass monitoring, help to provide a comprehensive image of the traits and requirements of the strains and allow control over specific fermentation processes. Yeasts are single-cell microorganisms that participate in pulque fermentation by producing ethanol and carbon dioxide while also assisting bacterial growth by creating vitamins, amino acids, and other metabolites.
They also provide the necessary aromatic constituents and proteolytic and lipolytic activities. The processes used to ferment yeast include alcoholic fermentations like beer, wine, and cider fermentation, as well as non-alcoholic yeast fermentations like coffee, bread, and chocolate fermentation. Yeasts are unicellular, eukaryotic microfungi found all over the natural world. They are part of the class of organisms known as fungi, which also include mushrooms and molds.
COVID-19 Impact Analysis
Markets worldwide started focusing on microbial strain production technology as it increased the output of microbial-based medications. Additionally, the government supports both small and large biotechnology companies in researching vaccinations, medicines, and products that improve gut health and boost immunity. Therefore, the pandemic aided in speeding up the R&D processes associated with the technology. But the closure of industries and disruptions of supply chains prevented the use of technology in any other sector. As a result, the pandemic had a moderate impact on the microbial fermentation technology market.
Market Growth Factors
Increasing demand for alcoholic beverages
Demand for alcoholic beverages has increased in establishments like hotels, restaurants, taverns, and pubs. Every year, wine, spirits, and beer are consumed worldwide in amounts of about 446 billion liters. Beer, lagers, and cider account for about 400 billion liters of all alcohol consumed, with wine and spirits coming in second and third, respectively. Additionally, the industry for alcoholic beverages is predicted to rise due to the growing demand for artisanal spirits in many developing nations. Therefore, as the demand for alcoholic beverages rises, it will propel the demand for microbial fermentation technology, which will ensure the market's growth.
Rising utilization of technology in food enrichment
The amount of protein in mechanically controlled canola meal increased after solid-state fermentation using Pleurotus ostreatus, and the amounts of glucosinolates and phytate decreased by up to 98.8% and 75.8%, respectively. In soybean meal (SBM), solid-state fermentation boosted the amino acid and protein content, with B. subtilis having a bigger influence than A. oryzae. These established experimental results have expanded the use cases for microbial fermentation technology. Hence, the microbial fermentation technology market will expand in the coming years owing to all these factors.
Market Restraining Factors
Issues associated with the fermentation process
Fermented products can be contaminated over time as they undergo continual natural variations. However, contamination through contamination sources is easy even if no variation occurs. Additionally, the product needs more processing because it is impure. The result was unintended and unpleasant; bad germs grew and multiplied while beneficial microbes perished. Some common fermentation processes, like solid state fermentation, have some drawbacks, including using microorganisms that can only withstand low moisture levels and the inability to precisely monitor SSF. Therefore, such difficulties associated with the microbial fermentation processes may hamper the market's growth in the coming years.
Application Outlook
Based on application, the microbial fermentation technology market is categorized into antibiotics, probiotics supplements, monoclonal antibodies, recombinant proteins, biosimilars, vaccines, enzymes, small molecules, and others. The monoclonal antibodies segment procured a considerable growth rate in the microbial fermentation technology market in 2021. One of the most useful biologics for various applications is monoclonal antibodies. These compounds' high binding affinity, selectivity, and specificity often make them advantageous.
End User Outlook
On the basis of end-user, the microbial fermentation technology market is divided into bio-pharmaceutical companies, contract research organizations (CROs), CMOs & CDMOs, and academic & research institutes. The contract manufacturing organizations (CROs) and contract development & manufacturing organization (CDMOs) segment witnessed the largest revenue share in the microbial fermentation technology market in 2021. CMOs and CDMOs are quickly evolving into the preferred choice for biotherapeutics producers because the majority of the invention in the bioprocess industry is produced by smaller businesses that lack the capacity, skilled personnel, and resources necessary for the development of these products.
Regional Outlook
Region wise, the microbial fermentation technology market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment procured the maximum revenue share in the microbial fermentation technology market in 2021. This results from acknowledging Asian nations as a center for outsourcing in the biopharmaceutical industry. An estimated 50% of new bioprocessing facilities worldwide are being built by Asian businesses, including domestic competitors and international powerhouses. For example, China plans to build several bioprocessing facilities to accommodate domestic demand.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biocon Limited, BioVectra Inc. (H.I.G. Capital, LLC), Danone S.A., F. Hoffmann-La Roche Ltd., Koninklijke DSM N.V., Lonza Group AG, Novozymes A/S (Novo Holdings A/S), Corbion N.V., and Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN).
Strategies Deployed in Microbial Fermentation Technology Market
Feb-2023: Danone opened a new Research and Innovation Center in Paris. The new research center would enable the company to develop and innovate fresh dairy and plant-based products and 'natural mineral water' categories.
Nov-2022: Biocon took over Viatris, Inc., an American pharmaceutical and healthcare corporation. The acquisition enable the company to emerge as a leading biosimilar player with eight commercialized products. Additionally, it would improve the research and development, global-scale manufacturing, and commercialization abilities of the company.
Nov-2022: BioVectra Inc. unveiled single-use fermentation microbial technology. The new technology contains 100 L and 1,000 L single-use fermenters. The single-use fermentation microbial technology would allow the company to provide greater flexibility, faster turnaround times, and increased capacity utilization to its customers.
Jul-2022: Novozymes introduced Innova Apex and Innova Turbo. The two new advanced yeasts are intended to break down fermentation bottlenecks and at the same time decrease the demand for urea, and also improve ethanol yield. The yeasts maximize the fermentation process, thereby enabling ethanol producers to achieve their production targets. The Innova Apex pushes the plant to 36 & dry solids and decreases glycerol by 38%.
Sep-2021: BioVectra signed an agreement with ABEC, a customized process solutions and services provider. The integration of ABEC CSR single-use fermentation solutions would enhance BIOVECTRA's high-growth microbial fermentation processes and would enable the company to offer a turnaround product to product and between batches.
Apr-2019: BioVectra Inc. expanded its geographical footprints in Windsor, Canada. The new manufacturing facility enables the company to manufacture substances to be used in developing treatments for cancer, autoimmune diseases, and diabetes.
Mar-2019: DSM and Cargill, agricultural, financial, and industrial products provider, together launches Avansya, a producer of produce zero-calorie, great-tasting sweeteners through fermentation. Avansya would produce sweet-tasting molecules, such as steviol glycosides Reb M and Reb D through a fermentation process.
Market Segments covered in the Report:
By Application
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research